liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder
Hyvinkaa Hospital, Finland; Helsinki University Hospital, Finland.
Karolinska University, Sweden.
Helsinki University Hospital, Finland.
University of Stavanger, Norway.
Show others and affiliations
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 5, 360-368 p.Article in journal (Refereed) Published
Abstract [en]

Objective: The aim of this study was to compare the long-term efficacy of BCG monotherapy to alternating therapy of mitomycin C (MMC) and BCG in patients with carcinoma in situ (CIS). Materials and methods: Between 1992 and 1997, 321 patients with CIS were randomized from Finland, Norway and Sweden in a prospective multicenter trial into two treatment groups. The alternating therapy comprised six weekly instillations of MMC 40 mg followed by 10 instillations of BCG (Connaught 120 mg) or MMC alternating monthly for 1 year. BCG monotherapy followed the same 6 + 10 schedule. Stratification was done by nationality and CIS category. Primary endpoints were time to first recurrence and time to progression. Secondary endpoints were disease-specific mortality and overall survival. The main statistical methods were the proportional subdistribution hazards model and Cox proportional hazards model with the cumulative incidence and Kaplan-Meier analyses. Results: The median follow-up time was 9.9 years (maximum 19.9 years) in the BCG group and 8.9 years (maximum 20.3 years) in the alternating group. The risk of recurrence was significantly lower in the BCG group than in the alternating group (49 vs 59% at 15 years, respectively; hazard ratio 0.74, 95% confidence interval 0.54-1.00, p = 0.048). There were no significant differences in the other endpoints. Patients who progressed after 2 years were particularly prone to dying from bladder carcinoma. Younger patients performed worse than older ones. Conclusions: BCG monotherapy including monthly maintenance was effective and better than the alternating therapy. The risk of dying from bladder carcinoma after progression was high.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2016. Vol. 50, no 5, 360-368 p.
Keyword [en]
BCG; carcinoma in situ; combination therapy; immunotherapy; instillation therapy; long-term efficacy; mitomycin C; randomized controlled trial; urinary bladder
National Category
Urology and Nephrology
Identifiers
URN: urn:nbn:se:liu:diva-132208DOI: 10.1080/21681805.2016.1210672ISI: 000384068000006PubMedID: 27603424OAI: oai:DiVA.org:liu-132208DiVA: diva2:1043950
Available from: 2016-11-01 Created: 2016-10-21 Last updated: 2016-11-01

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jahnson, Staffan
By organisation
Division of Clinical SciencesFaculty of Medicine and Health SciencesDepartment of Urology in Östergötland
In the same journal
Scandinavian journal of urology
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 7 hits
ReferencesLink to record
Permanent link

Direct link